CLINICAL_TRIALS
trial_result
· 2022-10-18
Clinical Trial Update: Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas [Phase 2]
Summary
Phase 2 clinical trial update for vistusertib (AZD2014) in recurrent grade II-III meningioma.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Massachusetts General Hospital | Conditions: Meningioma | Phase 2 | Status: UNKNOWN